Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...
Semaglutide, the diabetes and weight loss drug that’s commonly known as Ozempic, can help patients of peripheral artery ...
MaxStrength Fitness, a franchise concept that provides time-efficient and productive high-intensity strength training (HIT), nutritional consultation, and post-rehabilitation experiences in a boutique ...
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...
Novo Nordisk’s once‐weekly injectable, Ozempic (semaglutide), originally developed for type 2 diabetes, has increasingly ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
3d
March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Dialogue Health Technologies Inc. announced that it is the only virtual care provider to be awarded Accreditation with Exemplary Standing from Accreditation Canada, a globally recognized ...
SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...
Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback